Dec 7 2015
U.S. actor, Charlie Sheen’s recent announcement about his HIV status, World AIDS Day just last week, and the ongoing stories on HIV hot spots like Atlanta, GA make us realize that HIV is a persisting problem globally and in the U.S.
Dec 1 2015
In a US multi-site clinical study conducted to support FDA approval of G4, whole blood specimens were tested for HIV in urban clinics serving high risk populations.Read More
Apr 23 2015
Today, more than 1.2 million people in the United States are living with HIV, but as many as 168,000 (or 14%) remain unaware of their infection. In the US there are 50,000 new HIV infections reported every year, in part due to those people who unintentionally spread the disease simply because they do not know they are HIV positive. Helping people know...® has always been the inspiration driving MedMira forward, as it continues to evolve its rapid testing technology and applications.Read More
Jul 23 2014
According to the World Health Organization (WHO), more than 1 million people acquire a sexually transmitted infection every day. Organizations including the WHO have called on countries to create screening programs to combat the spread of these infections in a convenient, cost efficient, and timely manner. Traditional testing methods involve individual tests for each virus with a turnaround time of several days up to a week, which increases the cost to labs and wastes precious time for patients. With MedMira’s multiplex capable Multiplo tests, healthcare professionals can instantly screen for multiple disease states in several combinations using a single cartridge.Read More
May 15 2014
Rapid testing reinvented. That’s MedMira’s message as it looks to expand its presence in China where the size of the in vitro diagnostics (IVD) market is expected to grow by 20 percent each year.
Mar 10 2014
While the clinical healthcare market has had access to point-of-use testing for quite some time, there has never been a real-time analytical tool that researchers could use outside of lab settings to facilitate mobile antigen and antibody detection. Instead, they have long relied on traditional analyte testing technologies such as the ELISA and Western blot, which are technically challenging, inefficient and require a variety of components.